Clinical Trial

Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a low-intervention, randomized, non-comparative, open-label, multicenter, prospective, phase II trial investigating discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-01-12; most recent amendment 2025-04-30.
Status change: Not Yet Recruiting → Recruiting 2024-01-24
Trial Details
NCT Number NCT06207734
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Conditions Breast Cancer
Enrollment 120 participants
Start Date 2024-01-17
Primary Completion 2027-01-10 (estimated)
Study Completion 2028-07-10 (estimated)
Updated on ClinicalTrials.gov 2025-05-01